@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAjJ--QIWJuyyq2hGAC9gOpRqZ4PZpDlGyfuXUhr739dI> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAjJ--QIWJuyyq2hGAC9gOpRqZ4PZpDlGyfuXUhr739dI#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 geneProductOf: hgnc:10471 ;
    a Protein: .
  sub:_2 occursIn: species:9606 ;
    rdf:object sub:_1 ;
    rdf:predicate belv:increases ;
    rdf:subject chebi:52717 ;
    a rdf:Statement .
  sub:assertion rdfs:label "a(CHEBI:bortezomib) -> p(HGNC:RUNX1)" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_4 ;
    pav:version "1.4" .
  sub:_3 prov:value "Treatment of cells with the proteasome inhibitor PS341 (Velcade, Bortezomib) increases the levels of ubiquitinated AML1c. Mutation of the four phosphorylation sites necessary for transcriptional regulation (serine 276, serine 293, serine 303, and threonine 300) mimics the effects of the proteasome inhibitor, increasing the levels of ubiquitinated, matrix-bound AML1c." ;
    prov:wasQuotedFrom pubmed:16046550 .
  sub:_4 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:16046550 ;
    prov:wasDerivedFrom beldoc: , sub:_3 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:30:37.014+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}